A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software ...

A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...

Torrent has signed definitive agreements to acquire stake in JB Pharma at an equity valuation of Rs256.89bn ($3bn) on a fully ...

As the pharma sector braces for sector-specific tariffs from President Trump, what could the impact look like on supply ...